Health TrialsbyHealthPanel

Clinical trials

6

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer

Participants needed: 185
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Verastem, Inc.Updated: Oct 13, 2026Locations: 34
Eligibility criteria

Histologic or cytologic confirmed PDAC [+3]

Have any documented co-existing pathogenic or likely pathogenic RAS mutation(s)... [+10]

Read more
Status: Recruiting

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer

Participants needed: 150
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Verastem, Inc.Updated: Oct 9, 2026Locations: 23
Eligibility criteria

Histopathology confirmed metastatic CRC [+7]

Have any other documented co-existing common RAS mutation(s) [+10]

Read more
Status: Recruiting

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer

Participants needed: 105
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Verastem, Inc.Updated: Oct 7, 2026Locations: 19
Eligibility criteria

Histopathology confirmed unresectable locally advanced or metastatic NSCLC [+10]

Have any other documented co-existing common RAS mutation(s) [+10]

Read more
Status: Recruiting

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.

Participants needed: 270
Trial details
Phase: Phase 3Age: 18+Biological sex: FemaleType: InterventionalSponsor: Verastem, Inc.Updated: Oct 7, 2026Locations: 106
Eligibility criteria

Histologically proven LGSOC (ovarian, fallopian, peritoneal) [+9]

Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy. [+16]

Read more
Status: Not yet recruiting

Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

This Open-Label Extension (OLE) study provides participants with recurrent low-grade serous ovarian cancer (LGSOC) who have completed the VS-6766-201(RAMP-201) study continued, uninterrupted access to avutometinib in combination with defactinib. The study is designed to support patients in France with access to avutometinib and defactinib who maintain ongoing clinical benefit while collecting safety and tolerability data during extended treatment. Participation is restricted to patients transferring directly from VS-6766-201(RAMP-201), ensuring continuity of care without enrollment of new patients.

Participants needed: 2
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: Verastem, Inc.Updated: Aug 5, 2026Locations: 2
Eligibility criteria

Currently active on VS-6766-201(RAMP-201) study while receiving avutometinib in... [+3]

Radiographic or clinical disease progression or discontinuation of treatment for... [+8]

Read more
Status: Recruiting

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

Participants needed: 295
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Verastem, Inc.Updated: Apr 22, 2026Locations: 14
Eligibility criteria

Individuals ≥18 years of age. [+8]

Underwent major surgical procedure as defined by the Investigator, other than fo... [+7]

Read more